CA2487428A1 - Cd200-receptor mediated modulation of bone development - Google Patents

Cd200-receptor mediated modulation of bone development Download PDF

Info

Publication number
CA2487428A1
CA2487428A1 CA002487428A CA2487428A CA2487428A1 CA 2487428 A1 CA2487428 A1 CA 2487428A1 CA 002487428 A CA002487428 A CA 002487428A CA 2487428 A CA2487428 A CA 2487428A CA 2487428 A1 CA2487428 A1 CA 2487428A1
Authority
CA
Canada
Prior art keywords
receptor
bone
cd200r
use according
test compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002487428A
Other languages
English (en)
French (fr)
Inventor
Reginald M. Gorczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2487428A1 publication Critical patent/CA2487428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002487428A 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development Abandoned CA2487428A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38656402P 2002-06-07 2002-06-07
US60/386,564 2002-06-07
PCT/CA2003/000823 WO2003103709A2 (en) 2002-06-07 2003-06-06 Modulation of bone development

Publications (1)

Publication Number Publication Date
CA2487428A1 true CA2487428A1 (en) 2003-12-18

Family

ID=29736181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002487428A Abandoned CA2487428A1 (en) 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development

Country Status (6)

Country Link
US (3) US20050287603A1 (https=)
EP (1) EP1532176A2 (https=)
JP (3) JP4763282B2 (https=)
AU (2) AU2003233721B2 (https=)
CA (1) CA2487428A1 (https=)
WO (1) WO2003103709A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
US8647871B2 (en) 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
WO2014113704A2 (en) 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
DE60034871T2 (de) * 1999-09-03 2008-01-17 Amgen Inc., Thousand Oaks Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
KR20040028601A (ko) * 2000-09-05 2004-04-03 더 락커펠러 유니버시티 파골세포-관련 수용체
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer

Also Published As

Publication number Publication date
JP2006501167A (ja) 2006-01-12
JP4763282B2 (ja) 2011-08-31
US20090214573A1 (en) 2009-08-27
AU2009217461A1 (en) 2009-10-15
JP2010285448A (ja) 2010-12-24
WO2003103709A3 (en) 2004-04-08
AU2003233721B2 (en) 2009-07-02
US20050287603A1 (en) 2005-12-29
WO2003103709A2 (en) 2003-12-18
US20110189201A1 (en) 2011-08-04
EP1532176A2 (en) 2005-05-25
AU2003233721A1 (en) 2003-12-22
JP2010155843A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
TWI636994B (zh) Ｄｋｋ１抗體及使用方法
Costagliola et al. Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity
EP1735445B1 (en) Methods of modulating immune responses by modulating tim-1 and tim-4 function
KR20040004509A (ko) 신규단백질 및 그 제조방법
US20030215450A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
CN101830974A (zh) 淀粉样β(1-42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
US20160175401A1 (en) Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
US20150125459A1 (en) Apelin peptides, antibodies thereto, and methods of use
KR20010085767A (ko) 결합 조직 성장 인자를 조정, 조절 및 억제함에 의하여신장 장애를 검출, 예방 및 치료하는 방법
US20040171117A1 (en) Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders
JP2006522103A (ja) ＴＧＦβ結合タンパク質のリガンドおよびその使用
US20110189201A1 (en) Modulation of bone development
Rosen The cellular and clinical parameters of anabolic therapy for osteoporosis
JP2002515444A (ja) 骨粗鬆症の治療方法
EP2150819B1 (en) S100a9 interaction screening method
WO2007112386A2 (en) Gdf-9/bmp-15 modulators for the treatment of bone disorders
AU2002230466B2 (en) Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
JP2006507804A (ja) 単一ドメインｔｄｆ関連化合物およびその類似体
US7169559B2 (en) LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
AU2002230466A1 (en) Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
EP4554577A1 (en) Novel use
JP2006501167A5 (https=)
US20040213788A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
EP1389233A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20040005997A1 (en) Methods for identifying compounds for regulating muscle mass of function using amylin receptors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130703